Dow Jones

40,211.72

0.53%

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XLRN

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 12 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
17/05/2018	08:21	Business Wire	Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association	NASDAQ:XLRN	Acceleron Pharma Inc
11/05/2018	16:01	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XLRN	Acceleron Pharma Inc
11/05/2018	15:59	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:XLRN	Acceleron Pharma Inc
08/05/2018	15:29	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:XLRN	Acceleron Pharma Inc
08/05/2018	15:01	Business Wire	Acceleron Reports First Quarter 2018 Operating and Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
02/05/2018	06:00	Business Wire	Acceleron to Participate in Two Healthcare Investor Conferences in May	NASDAQ:XLRN	Acceleron Pharma Inc
01/05/2018	06:00	Business Wire	Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy (FSHD)	NASDAQ:XLRN	Acceleron Pharma Inc
30/04/2018	06:00	Business Wire	Acceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018	NASDAQ:XLRN	Acceleron Pharma Inc
26/04/2018	07:00	Business Wire	Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting	NASDAQ:XLRN	Acceleron Pharma Inc
26/04/2018	06:00	Business Wire	Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology An...	NASDAQ:XLRN	Acceleron Pharma Inc
13/04/2018	15:21	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:XLRN	Acceleron Pharma Inc
13/04/2018	15:19	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:XLRN	Acceleron Pharma Inc
12/03/2018	06:00	Business Wire	Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH)...	NASDAQ:XLRN	Acceleron Pharma Inc
28/02/2018	06:04	Business Wire	Acceleron Announces Publication of ACE-083 Phase 1 Trial Results in Muscle & Nerve	NASDAQ:XLRN	Acceleron Pharma Inc
27/02/2018	16:49	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:XLRN	Acceleron Pharma Inc
27/02/2018	15:27	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:XLRN	Acceleron Pharma Inc
27/02/2018	15:05	Business Wire	Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
20/02/2018	06:00	Business Wire	Acceleron to Webcast Fourth Quarter and Full Year 2017 Operating and Financial Results on February 27, 2018	NASDAQ:XLRN	Acceleron Pharma Inc
14/02/2018	13:19	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:XLRN	Acceleron Pharma Inc
13/02/2018	16:49	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:XLRN	Acceleron Pharma Inc
08/02/2018	15:01	Business Wire	Acceleron Announces Appointment of Chief Commercial Officer	NASDAQ:XLRN	Acceleron Pharma Inc
08/02/2018	09:47	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:XLRN	Acceleron Pharma Inc
31/01/2018	06:00	Business Wire	Acceleron to Present at the Leerink Partners 7th Annual Global Healthcare Conference	NASDAQ:XLRN	Acceleron Pharma Inc
08/01/2018	10:05	Business Wire	Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy	NASDAQ:XLRN	Acceleron Pharma Inc
03/01/2018	06:00	Business Wire	Acceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. Sherman	NASDAQ:XLRN	Acceleron Pharma Inc
02/01/2018	06:00	Business Wire	Acceleron to Webcast Presentation at the 36th Annual J.P. Morgan Healthcare Conference	NASDAQ:XLRN	Acceleron Pharma Inc
10/12/2017	08:00	Business Wire	Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annu...	NASDAQ:XLRN	Acceleron Pharma Inc
05/12/2017	06:00	Business Wire	Acceleron to Host Conference Call & Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meetin...	NASDAQ:XLRN	Acceleron Pharma Inc
28/11/2017	12:15	Edgar (US Regulatory)	Confidential Treatment Order (ct Order)	NASDAQ:XLRN	Acceleron Pharma Inc
15/11/2017	15:01	Business Wire	Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire	NASDAQ:XLRN	Acceleron Pharma Inc